Continuity of Care in Swiss Cancer Patients Using Claims Data.

BACKGROUND

Continuity of care is positively associated with beneficial patient outcomes. Data on the level of continuity of care in the ambulatory setting in Switzerland are lacking.

AIM

The aim of this study was to evaluate continuity of care in Swiss cancer patients based on routine data of mandatory health insurance using four established continuity scales.

METHODS

Retrospective analysis of Swiss claims data (N=23'515 patients with incident use of antineoplastics). The Usual Provider Continuity score, the Modified Modified Continuity Index, the Continuity of Care index, and the Sequential Continuity Index were analyzed based on consultations with general practitioners (GPs), physician specialists and ambulatory hospital wards.

RESULTS

Using information of health insurance claims, the number of consultations and the general level of continuity of care in Swiss cancer patients are high. Continuity of care scores were significantly associated with sociodemographic and regional factors. When focusing on consultations with GPs only, all four scores consistently showed high values indicating high levels of continuity. Continuity with general practitioners was associated with lower costs and lower risks for hospitalization and death.

CONCLUSION

This is the first study giving insight into continuity of care in Swiss cancer patients. The present study shows that continuity of care is measurable using health insurance claims data. It indicates that continuity with general practitioners is associated with a beneficial outcome.

Informations de copyright

© 2020 Blozik et al.

Déclaration de conflit d'intérêts

Eva Blozik, Caroline Bähler, and Markus Näpflin are employees of Helsana Group. Dr Eva Blozik reports grants from Swiss Cancer Research Foundation, during the conduct of the study; grants from Novartis Pharma, Amgen Switzerland, MSD Switzerland, Vifor Pharma, and Swiss Cancer Research Foundation, outside the submitted work. Mr Markus Näpflin reports grants from Novartis Pharma Switzerland, MSD, Amgen, and Vifor, outside the submitted work. The authors report no other conflicts of interest in this work.